Safety in Lactation: Diuretics

21 October 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Thiazides and related diuretics (includes bendroflumethiazide,…

What medicines should be avoided by patients suffering from “sulfa allergy”?

12 June 2020This updated Medicines Q&A evaluates the limited evidence available on cross-sensitivity between sulfonamide-containing medicines and lists classes of medication that contain a sulfonamide in their…
Search Articles

Medicine Compliance Aid Stability

genericTeva UK Ltd

Teva UK Ltd
Tablets 1mg, 5mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from light. Store in airtight containers. Bumetanide is photosensitive and will discolor when exposed to light.
9 November 2015

Lactation Safety Information

No published evidence of safety
24 February 2017

New Medicines

Autism in children and adolescents


Re-purposed drug

Development and Regulatory status

Sep 21Development discontinued. No sign of effectiveness was observed in the two PIII studies assessing bumetanide versus placebo in the treatment of ASD in children and adolescents. As a consequence, early discontinuation of the two clinical studies has been decided by the sponsor [10].


Loop diuretic in a oral liquid formulation; ion pump modulator. Some neurodevelopmental disorders are associated with high sodium levels in neurons, which are reduced by bumetanide.
Estimates suggest that about 1% of people in the UK have autistic spectrum disorder (ASD) [3] and a study published in 2013 found UK annual prevalence rates for autism at age 8 of 3.8/1000 for boys and 0.8/1000 for girls, and annual incidence rates for children aged 2-8 of 1.2/1000 and 0.2/1000 respectively, with rates steady from the early 2000s [4].
Autism in children and adolescents